Background: Ceramic femoral heads with titanium sleeves are commonly used in revision total hip arthroplasty (rTHA). Companies advise against combination with a retained femoral component from another manufacturer. However, no data are available. The aim of this study was to evaluate and compare the implant failure and revision rates of ceramic heads with a 12/14 titanium sleeve used on manufacturer-compatible versus noncompatible retained femoral components.

Methods: A retrospective single-center cohort analysis was performed using a prospectively maintained institutional arthroplasty registry. We identified 439 patients who received a titanium 12/14 ceramic head during rTHA between January 1, 2007, and December 31, 2022. There were 229 manufacturer-compatible and 210 manufacturer-noncompatible retained femoral stems, according to the company's official product compatibility list. Implant failure and rerevision rates were evaluated.

Results: After a median follow-up of 6.6 years (IQR (interquartile range): 4.5 to 9.3), there was no significant difference (P = 0.770) in the rerevision rate between the manufacturer-compatible group (17.0%) and the noncompatible group (18.1%). Revision-free survival after rTHA was 81.2% in the manufacturer-compatible group and 78.9% in the manufacturer-noncompatible group after 15 years (P = 0.653). Most rerevisions occurred in the first year after rTHA, with 29 of 229 (12.7%) in the manufacturer-compatible group and 24 of 210 (11.4%) in the manufacturer-noncompatible group (P = 0.705). We observed only one implant failure in the manufacturer-noncompatible group, but this was not related to a mismatch problem.

Conclusions: Although legal uncertainties remain, this study showed no increased risk of implant failure or revision rates when a ceramic femoral head, with a 12/14 titanium sleeve, was used on a noncompatible femoral stem from a manufacturer.